<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281929</url>
  </required_header>
  <id_info>
    <org_study_id>2014_05</org_study_id>
    <secondary_id>2014-002536-13</secondary_id>
    <secondary_id>PHRC-2013-0552</secondary_id>
    <nct_id>NCT02281929</nct_id>
  </id_info>
  <brief_title>Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone</brief_title>
  <acronym>AntibioCor</acronym>
  <official_title>Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of reference of severe alcoholic hepatitis is based on corticosteroids, given for
      28 days. However, about 25-35% of patients do not take benefit from this treatment and die
      within the 6 months following the diagnosis. Numerous trials have evaluated the impact of
      several strategies in association with corticosteroids. None of them has shown an improvement
      in survival (primary endpoint) as compared to corticosteroids alone.

      The project is based on an approach never tested in a randomized controlled trial in severe
      alcoholic hepatitis, targeting the group of patients at high risk of death (25-35% at 2
      months). This approach is based on animal and human studies.Antibiotics are effective in
      animal models and in other circumstances characterized by liver failure such as
      gastrointestinal bleeding related to portal hypertension. The interest of studying this
      population is emphasized by the frequency of infections in these critically ill patients.
      Antibiotics will be administered before the development of any infection, as it is likely
      that these patients present with mesenteric bacterial adenitis without systemic signs of
      infection. Primary endpoint will be 2-month survival as most deaths occur within 60 days and
      treatment is given for 30 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter double-blind randomized controlled study on two parallel groups.

      Once inclusion and exclusion criteria verified and after having obtained patient written
      consent, participative centers will process to inclusion in the trial.

      Corticosteroids as well as antibiotics or their placebo will be started orally. Patients will
      be managed in the hospital unit until day 7, which corresponds to the evaluation of response
      to treatment using the Lille model. After this 7-day period, patients will be followed-up at
      day 14, day 21, day 30, day 60 (primary endpoint).

      During each visit, biological and clinical features including efficacy and tolerance will be
      assessed as well as presence of infection and hepatorenal syndrome (secondary endpoints).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient alive</measure>
    <time_frame>at day 60</time_frame>
    <description>The percentage of patients alive at 2 months in the experimental arm compared to the percentage of patients alive in the control arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>at day 7, day14, day 21, day 30, day 60; at 3 months, at 6 months</time_frame>
    <description>incidence of infection over the 2-month period in the antibiotic+corticosteroid arm as compared to the control arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatorenal syndrome</measure>
    <time_frame>at day 7, day14, day 21, day 30,at 3 months, at 6 months</time_frame>
    <description>incidence of hepatorenal syndrome over the 2-month period in the antibiotic+corticosteroid arm as compared to the control arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MELD score &lt;17</measure>
    <time_frame>at day 7, day14, day 21, day 30,</time_frame>
    <description>percentage of patients with a low risk of mortality during the first two months (assessed by a MELD score &lt;17) in the two arms of treatment. The MELD score will be calculated using the following formula:(9.57 × log creatinine in milligrams per deciliter) + (3.78 × log bilirubin in milligrams per deciliter) + (11.20 × log international normalized ratio) + 6.43.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lille Model</measure>
    <time_frame>at day 7, after the first administration of treatment</time_frame>
    <description>percentage of patients disclosing a response to treatment assessed by the Lille model (&lt;0.45) in the two arms of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient alive</measure>
    <time_frame>at 3 months, at 6 months</time_frame>
    <description>The percentage of patients alive at 2 months in the experimental arm compared to the percentage of patients alive in the control arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <condition>Alcoholic Liver Disease</condition>
  <arm_group>
    <arm_group_label>amoxicillin+ prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral antibiotherapy during 30 days using amoxicillin+clavulanic acid at a daily dose of 3 gram (amoxicillin) and 375 mg (clavulanic acid) in three daily doses of 1g/125mg. Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + prednisolone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo of amoxicillin- clavulanic acid in three daily doses during 30 days Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days</description>
    <arm_group_label>amoxicillin+ prednisolone</arm_group_label>
    <other_name>Amoxicillin + clavulanic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in three daily doses during 30 days</description>
    <arm_group_label>Placebo + prednisolone</arm_group_label>
    <other_name>Placebo of amoxicillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days</description>
    <arm_group_label>amoxicillin+ prednisolone</arm_group_label>
    <arm_group_label>Placebo + prednisolone</arm_group_label>
    <other_name>corticotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-75

          -  Recent onset of jaundice (&lt;3 months)

          -  Biopsy proven alcoholic hepatitis (transjugular liver biopsy)

          -  Maddrey's discriminant function ≥ 32, defining severe alcoholic hepatitis

          -  MELD score ≥21

          -  Alcohol consumption ≥ 40g/day (women) and ≥ 50g/day (men)

          -  Written informed consent

        Exclusion Criteria:

          -  Previous severe allergy or hypersensitivity to amoxicillin or clavulanic acid
             (anaphylactic shock, Quincke edema, severe urticaria)

          -  Hypersensitivity to any component of the medication

          -  History of liver injury to amoxicillin and/or clavulanic acid

          -  Phenylketonuria, because of the presence of aspartame in the powder for the oral
             suspension

          -  Type 1 hepatorenal syndrome before the initiation of treatment

          -  Severe extrahepatic disease

          -  Any malignant tumor &lt; 2 years

          -  Uncontrolled gastrointestinal bleeding

          -  Ongoing viral or parasitic infection

          -  Untreated bacterial infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathurin Philippe, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathurin Philippe, MD,PhD</last_name>
    <email>phillippe.mathurin@chru-lille.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louvet Alexandre, MD,PhD</last_name>
    <email>alexandre.louvet@chru-lille.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric N'Guyen khac, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François Oberti, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thierry Thevenot, MD,</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Verdier (AH-HP)</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Nahon, MD</last_name>
    </contact>
    <investigator>
      <last_name>pierre Nahon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thong DAO, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital BEaujon (AP-HP)</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>A Payance, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>thierry Paupard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent Leroy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez, CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Louvet, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Mathurin, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Louvet, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georges Pageaux, Md,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>J Gournay, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rodolphe Anty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Carbonell, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas Carbonell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié (AP-HP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominique Thabut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine Sylvain, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>L Legros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>O Goria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chritophe Bureau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faustine Wartel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Faustine Wartel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse (AH-HP)</name>
      <address>
        <city>Villejuif</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J-C Duclos-Vallée</last_name>
    </contact>
    <investigator>
      <last_name>J-C Duclos-Vallée, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.lillemodel.com/</url>
  </link>
  <reference>
    <citation>Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011 Feb;60(2):255-60. doi: 10.1136/gut.2010.224097. Epub 2010 Oct 12.</citation>
    <PMID>20940288</PMID>
  </reference>
  <reference>
    <citation>Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL; AAH-NAC Study Group. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011 Nov 10;365(19):1781-9. doi: 10.1056/NEJMoa1101214.</citation>
    <PMID>22070475</PMID>
  </reference>
  <reference>
    <citation>Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009 Jun 25;360(26):2758-69. doi: 10.1056/NEJMra0805786. Review.</citation>
    <PMID>19553649</PMID>
  </reference>
  <reference>
    <citation>Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, Deltenre P, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009 Aug;137(2):541-8. doi: 10.1053/j.gastro.2009.04.062. Epub 2009 May 13.</citation>
    <PMID>19445945</PMID>
  </reference>
  <reference>
    <citation>Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Canva V, Pruvot FR, Mathurin P. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007 Jun;45(6):1348-54.</citation>
    <PMID>17518367</PMID>
  </reference>
  <reference>
    <citation>Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, Anty R, Diaz E, Thabut D, Moirand R, Lebrec D, Moreno C, Talbodec N, Paupard T, Naveau S, Silvain C, Pageaux GP, Sobesky R, Canva-Delcambre V, Dharancy S, Salleron J, Dao T. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013 Sep 11;310(10):1033-41. doi: 10.1001/jama.2013.276300.</citation>
    <PMID>24026598</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcoholic hepatitis</keyword>
  <keyword>corticotherapy</keyword>
  <keyword>antibiotherapy</keyword>
  <keyword>survival</keyword>
  <keyword>infection</keyword>
  <keyword>hepato renal syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

